Dub Therapeutics Inc.

Syracuse, NY

UEI
RNZAEDZ7WJG2
CAGE
9Z0D4
Primary NAICS
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Woman Owned Small Business
  • Woman Owned Business
  • Black American Owned
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
505 Irving Ave Rm 3721, Syracuse, NY 13210, USA
Website
dubtx.com

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Dub Therapeutics Inc.'s 2 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
A novel sirna therapeutic to prevent scarring and bleb failure after trabeculectomy - abstract glaucoma is the leading… Grant · R44EY038138 National Eye Institute $1,009,285
A single dose anti-scarring therapeutic for the cornea - abstract DUB biologics is developing a therapeutic for the… Grant · R44EY035188 National Eye Institute $1,799,926

Quick answers

What is Dub Therapeutics Inc.'s UEI?

Dub Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is RNZAEDZ7WJG2.

What is Dub Therapeutics Inc.'s CAGE code?

Dub Therapeutics Inc.'s CAGE code is 9Z0D4.

What is Dub Therapeutics Inc.'s primary NAICS code?

Dub Therapeutics Inc.'s primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).

Where is Dub Therapeutics Inc. located?

Dub Therapeutics Inc.'s physical address in SAM.gov is 505 Irving Ave Rm 3721, Syracuse, NY 13210, USA.

Is Dub Therapeutics Inc. registered in SAM.gov?

Yes. Dub Therapeutics Inc.'s SAM.gov registration is active through May 18, 2027.

What is Dub Therapeutics Inc.'s most recent federal award?

Dub Therapeutics Inc.'s most recent federal grant award is A novel sirna therapeutic to prevent scarring and bleb failure after trabeculectomy - abstract glaucoma is the leading… (R44EY038138), from National Eye Institute, on September 15, 2025.

On GovTribe

See Dub Therapeutics Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login